Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography after Doxorubicin-Bleomycin-vinblastine-dacarbazine Chemotherapy Predicts Event-Free Survival in Hodgkin's Lymphoma

任旭升,王华庆,钱正子,周世勇,张会来,孟祥睿,赵静,王平
DOI: https://doi.org/10.3969/j.issn.1000-8179.2013.04.011
2013-01-01
Abstract:Objective: To evaluate the prognostic value of fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET/CT) after four cycles of chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for Hodgkin's lymphoma (HL) patients. Methods: The data of 62 HL patients were retrospectively analyzed between August 2005 and July 2009. All patients underwent standard ABVD therapy. After four cycles of ABVD, the patients were evaluated with 18F-FDG PET/CT. The prognostic value of 18F-FDG PET/CT in HL was analyzed. Results: Treatment failure was seen in 11 of the 18 PET/CT-positive patients (61.1%) and in only 5 of the 46 PET/CT-negative patients (11.4%). The treatment failure rate in PET/CT-positive patients was significantly higher than in the PET/CT-negative ones (P<0.01). The three-year event-free survival (EFS) was 44.4% for PET/CT-positive patients and 81.8% for PET/CT-negative ones (P<0.01). Univariate survival analysis revealed that 18F-FDG PET/CT was the independent predictive factor of three-year EFS for patients with HL (P<0.01). Conclusion: After four cycles of ABVD chemotherapy, PET/CT is found to be an independent predictor of EFS in HL. However, due to the limited number of patients in this study, the conclusion needs to be confirmed.
What problem does this paper attempt to address?